Moderna CFO out of job after two days

Jorge Gomez, who stepped into the role of CFO for Moderna May 9, is already out of a job.

The sudden departure was a result of an internal probe of financial reporting by Gomez’s former employer, Dentsply Sirona, American dental equipment manufacturer and dental consumables producer. Moderna is a Cambridge, Massachusetts-based pharmaceutical company and is one of three drug makers with approved COVID-19 vaccines in the U.S. Moderna announced Gomez left the job May 11.

Moderna cited “an ongoing internal investigation into certain matters” in its announcement. David Meline, who recently retired as CFO of Moderna, will resume the role, effective May 11, as the company searches for a replacement.

Dentsply Sirona announced it will be filing its Form 10-Q late as a result of the internal probe.

“The investigation is ongoing, and the company cannot predict the duration or outcome of the investigation,” stated an SEC filing from Dentsply Sirona. “As a result, the company has not yet finalized its financial statements or its assessment of the impact of the investigation on its historical financial statements or for the financial statements for the three months ended March 31, 2022, and is therefore unable to file the Form 10-Q on a timely basis.”

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.